LOS ALTOS, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- MultiValent Biotherapies, Inc. (MultiValent), a private biotechnology company developing targeted drug conjugate therapies for cancer, announced a ...
A combination of Merck’s islatravir and Gilead’s lenacapavir has succeeded in two phase 3 trials and is in line to become the first long-acting oral HIV treatment that can be taken weekly. Both trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results